Back to top
more

Exagen (XGN)

(Delayed Data from NSDQ)

$9.20 USD

9.20
166,824

+0.21 (2.34%)

Updated Aug 8, 2025 04:00 PM ET

After-Market: $9.18 -0.02 (-0.22%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (155 out of 244)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Exagen Inc. (XGN) Reports Q2 Loss, Beats Revenue Estimates

by Zacks Equity Research

Exagen (XGN) delivered earnings and revenue surprises of 0.00% and +7.51%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Exagen (XGN) Soars 5.5%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Exagen (XGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

Exagen Inc. (XGN) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Exagen (XGN) delivered earnings and revenue surprises of 0% and 8.38%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Exagen Inc. (XGN) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Exagen (XGN) delivered earnings and revenue surprises of 25.93% and 1.15%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Curaleaf Holdings, Inc. (CURLF) Q4 Earnings Top Estimates

by Zacks Equity Research

Curaleaf Holdings, Inc. (CURLF) delivered earnings and revenue surprises of 128.57% and 0.25%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Green Thumb Industries Inc. (GTBIF) Lags Q4 Earnings Estimates

by Zacks Equity Research

Green Thumb Industries Inc. (GTBIF) delivered earnings and revenue surprises of -20% and 1.61%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Strength Seen in Exagen (XGN): Can Its 29.4% Jump Turn into More Strength?

by Zacks Equity Research

Exagen (XGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

Exagen Inc. (XGN) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Exagen (XGN) delivered earnings and revenue surprises of 6.67% and 7.70%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Bio-Rad Laboratories (BIO) Beats Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Bio-Rad (BIO) delivered earnings and revenue surprises of 57.03% and 2.02%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Bears are Losing Control Over Exagen (XGN), Here's Why It's a 'Buy' Now

by Zacks Equity Research

After losing some value lately, a hammer chart pattern has been formed for Exagen (XGN), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Zacks Equity Research

Exagen (XGN) Shows Fast-paced Momentum But Is Still a Bargain Stock

by Zacks Equity Research

Exagen (XGN) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.

Zacks Equity Research

Exagen Inc. (XGN) Soars to 52-Week High, Time to Cash Out?

by Zacks Equity Research

Exagen (XGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

Fast-paced Momentum Stock Exagen (XGN) Is Still Trading at a Bargain

by Zacks Equity Research

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Exagen (XGN) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

Zacks Equity Research

Exagen Inc. (XGN) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Exagen (XGN) delivered earnings and revenue surprises of 55.56% and 14.12%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Why Fast-paced Mover Exagen (XGN) Is a Great Choice for Value Investors

by Zacks Equity Research

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Exagen (XGN) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

Sanghamitra Saha headshot

Time to Play 5 Top-Ranked Stocks With Rising P/E?

by Sanghamitra Saha

Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include AMC Entertainment (AMC), Exagen (XGN), Health Catalyst (HCAT), CLEAR Secure (YOU) and Applied DNA Sciences (APDN).

Zacks Equity Research

Exagen Inc. (XGN) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Exagen (XGN) delivered earnings and revenue surprises of 52.50% and 9.21%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Quanterix Corporation (QTRX) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Quanterix (QTRX) delivered earnings and revenue surprises of 21.21% and 1.09%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Exagen Inc. (XGN) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Exagen Inc. (XGN) delivered earnings and revenue surprises of 24.39% and 20.40%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Cresco Labs Inc. (CRLBF) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Cresco Labs Inc. (CRLBF) delivered earnings and revenue surprises of 150% and 3.80%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Zynex Inc. (ZYXI) Q4 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Zynex Inc. (ZYXI) delivered earnings and revenue surprises of -76.47% and 12.44%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Despite Fast-paced Momentum, Exagen Inc. (XGN) Is Still a Bargain Stock

by Zacks Equity Research

Exagen Inc. (XGN) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.

Zacks Equity Research

Exagen Inc. (XGN) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Exagen Inc. (XGN) delivered earnings and revenue surprises of 41.67% and 28.92%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Exagen Inc. (XGN) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Exagen Inc. (XGN) delivered earnings and revenue surprises of 15.38% and 18.21%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Veru Inc. (VERU) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Veru Inc. (VERU) delivered earnings and revenue surprises of -33.33% and 66.06%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?